The use of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable
salt or solvate thereof, or solvate of said salt, and (B) a pharmaceutically acceptable
particulate diluent or carrier in an amount of from 400 g to 5000 g
per g of (A) for the preparation of an inhalable medicament for the treatment
of chronic obstructive pulmonary disease.
